BACKGROUND AND PURPOSE: As newer MR imaging techniques are used to assist with tumor grading, biopsy planning, and therapeutic response assessment, there is a need to relate the imaging characteristics to underlying pathologic processes. The aim of this study was to see how rCBV, a known marker of tumor vascularity, relates to cellular packing attenuation and cellular proliferation. MATERIALS AND METHODS: Nine patients with histologically proved high-grade gliomas and 1 with a supratentorial PNET requiring an image-guided biopsy were recruited. Patients underwent a DSC study. The rCBV at the intended biopsy sites was determined by using a histogram measure to derive the mean, maximum, and 75th centile and 90th centile values. This measure was correlated with histologic markers of the MIB-1 labeling index (as a marker of glioma cell proliferation) and the total number of neoplastic cells in a high-power field (cellular packing attenuation). RESULTS: There was a good correlation between rCBV and MIB-1 by using all the measures of rCBV. The mean rCBV provided the best results (r = 0.66, P < .001). The only correlation with cellular packing attenuation was with the 90% centile (rCBV(90%), r = 0.36, P = .03). The increase in rCBV could be seen over 1 cm from the edge of enhancement in 4/10 cases, and at 2 cm in 1/10. CONCLUSIONS: rCBV correlated with cellular proliferation in high-grade gliomas but not with cellular packing attenuation. The increase in rCBV extended beyond the contrast-enhancing region in 50% of our patients.
BACKGROUND AND PURPOSE: As newer MR imaging techniques are used to assist with tumor grading, biopsy planning, and therapeutic response assessment, there is a need to relate the imaging characteristics to underlying pathologic processes. The aim of this study was to see how rCBV, a known marker of tumor vascularity, relates to cellular packing attenuation and cellular proliferation. MATERIALS AND METHODS: Nine patients with histologically proved high-grade gliomas and 1 with a supratentorial PNET requiring an image-guided biopsy were recruited. Patients underwent a DSC study. The rCBV at the intended biopsy sites was determined by using a histogram measure to derive the mean, maximum, and 75th centile and 90th centile values. This measure was correlated with histologic markers of the MIB-1 labeling index (as a marker of glioma cell proliferation) and the total number of neoplastic cells in a high-power field (cellular packing attenuation). RESULTS: There was a good correlation between rCBV and MIB-1 by using all the measures of rCBV. The mean rCBV provided the best results (r = 0.66, P < .001). The only correlation with cellular packing attenuation was with the 90% centile (rCBV(90%), r = 0.36, P = .03). The increase in rCBV could be seen over 1 cm from the edge of enhancement in 4/10 cases, and at 2 cm in 1/10. CONCLUSIONS: rCBV correlated with cellular proliferation in high-grade gliomas but not with cellular packing attenuation. The increase in rCBV extended beyond the contrast-enhancing region in 50% of our patients.
Authors: N Sadeghi; I Salmon; C Decaestecker; M Levivier; T Metens; D Wikler; V Denolin; S Rorive; N Massager; D Baleriaux; S Goldman Journal: AJNR Am J Neuroradiol Date: 2007-03 Impact factor: 3.825
Authors: G Brasil Caseiras; J S Thornton; T Yousry; C Benton; J Rees; A D Waldman; H R Jäger Journal: AJNR Am J Neuroradiol Date: 2008-04-03 Impact factor: 3.825
Authors: Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez Journal: AJNR Am J Neuroradiol Date: 2004-02 Impact factor: 3.825
Authors: N Sadeghi; N D'Haene; C Decaestecker; M Levivier; T Metens; C Maris; D Wikler; D Baleriaux; I Salmon; S Goldman Journal: AJNR Am J Neuroradiol Date: 2007-12-13 Impact factor: 3.825
Authors: S J Price; R Jena; N G Burnet; P J Hutchinson; A F Dean; A Peña; J D Pickard; T A Carpenter; J H Gillard Journal: AJNR Am J Neuroradiol Date: 2006-10 Impact factor: 3.825
Authors: Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu Journal: Neurosurgery Date: 2019-08-01 Impact factor: 4.654
Authors: C P Geer; J Simonds; A Anvery; M Y Chen; J H Burdette; M E Zapadka; T L Ellis; S B Tatter; G J Lesser; M D Chan; K P McMullen; A J Johnson Journal: AJNR Am J Neuroradiol Date: 2011-11-24 Impact factor: 3.825
Authors: L S Hu; H Yoon; J M Eschbacher; L C Baxter; A C Dueck; A Nespodzany; K A Smith; P Nakaji; Y Xu; L Wang; J P Karis; A J Hawkins-Daarud; K W Singleton; P R Jackson; B J Anderies; B R Bendok; R S Zimmerman; C Quarles; A B Porter-Umphrey; M M Mrugala; A Sharma; J M Hoxworth; M G Sattur; N Sanai; P E Koulemberis; C Krishna; J R Mitchell; T Wu; N L Tran; K R Swanson; J Li Journal: AJNR Am J Neuroradiol Date: 2019-02-28 Impact factor: 3.825
Authors: Evan D H Gates; Jonathan S Lin; Jeffrey S Weinberg; Jackson Hamilton; Sujit S Prabhu; John D Hazle; Gregory N Fuller; Veera Baladandayuthapani; David Fuentes; Dawid Schellingerhout Journal: Neuro Oncol Date: 2019-03-18 Impact factor: 12.300
Authors: A Gupta; R J Young; A D Shah; A D Schweitzer; J J Graber; W Shi; Z Zhang; J Huse; A M P Omuro Journal: Clin Neuroradiol Date: 2014-01-29 Impact factor: 3.649